米氮平联合选择性钙通道拮抗剂治疗肠易激综合征有效性与安全性的Meta分析(6)
[32] POPA SL，LEUCUTA DC，DUMITRASCU DL. Pressure management as an occupational stress risk factor in irritable bowel syndrome：a cross-sectional study[J]. Medicine(Baltimore)，2018. DOI：10.1097/MD.0000000000013562.
[33] XU XJ，LIU L，YAO SK. Nerve growth factor and diarrhea-predominant irritable bowel syndrome(IBS-D)：a potential therapeutic target？ [J]. J Zhejiang Univ Sci B，2016，17(1)：1-9.
[34] WINDGASSEN S，MOSS-MORRIS R，GOLDSMITH K，et al. Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome：the importance of gastrointestinal related cognitions，behaviours and general anxiety[J]. J Psychosom Res，2018. DOI：10.1016/j.jpsychores.2018.11.013.
[35] TRIANTAFILLIDIS JK，MALGARINOS G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome：a literature review[J]. Clin Exp Gastroenterol，2014. DOI：10.2147/CEG.S46291.
[36] ALIKHAN SM，LEE JA，DRATCU L. Mirtazapine treatment of a severe depressive episode and resolution of elevated inflammatory markers[J]. Case Rep Psychiatry，2013. DOI：10.1155/2013/697872.
[37] ANTTILA SA，LEINONEN EV. A review of the pharmacological and clinical profile of mirtazapine[J]. CNS Drug Rev，2001，7(3)：249-264.
[38] THOMAS SG. Irritable bowel syndrome and mirtazapine[J]. Am J Psychiatry，2000，157(8)：1341-1342.
(收稿日期：2019-04-21 修回日期：2019-06-19)
(編辑：陈 宏), 百拇医药(蔡林坤 彭卓嵛 黄适 黄雅兰 陶丽芬 蓝斯莹)
[33] XU XJ，LIU L，YAO SK. Nerve growth factor and diarrhea-predominant irritable bowel syndrome(IBS-D)：a potential therapeutic target？ [J]. J Zhejiang Univ Sci B，2016，17(1)：1-9.
[34] WINDGASSEN S，MOSS-MORRIS R，GOLDSMITH K，et al. Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome：the importance of gastrointestinal related cognitions，behaviours and general anxiety[J]. J Psychosom Res，2018. DOI：10.1016/j.jpsychores.2018.11.013.
[35] TRIANTAFILLIDIS JK，MALGARINOS G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome：a literature review[J]. Clin Exp Gastroenterol，2014. DOI：10.2147/CEG.S46291.
[36] ALIKHAN SM，LEE JA，DRATCU L. Mirtazapine treatment of a severe depressive episode and resolution of elevated inflammatory markers[J]. Case Rep Psychiatry，2013. DOI：10.1155/2013/697872.
[37] ANTTILA SA，LEINONEN EV. A review of the pharmacological and clinical profile of mirtazapine[J]. CNS Drug Rev，2001，7(3)：249-264.
[38] THOMAS SG. Irritable bowel syndrome and mirtazapine[J]. Am J Psychiatry，2000，157(8)：1341-1342.
(收稿日期：2019-04-21 修回日期：2019-06-19)
(編辑：陈 宏), 百拇医药(蔡林坤 彭卓嵛 黄适 黄雅兰 陶丽芬 蓝斯莹)